In the News | Charles River
   
 
 
   
   

Similar or Better?
Pharma Magazine
July/August 2011

Follow the biosimilar pathway with reduced developmental costs, but low market share at a reduced price, or take the full development cost knowing that the product is more likely to reach the market in a form that will capture a potentially larger share of the indication market at a premium price? Which is better? The answers will tell us a great deal about the future of the biopharma industry.

Click here to read the full article from Pharma Magazine.

 

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
mai 14 - New Models for Evaluating COPD or ...
mai 11 - Expert Safety Testing to Accelerat...
juin 17-juin 20 -  Noordwijk aan Zee, the Netherlands - 19th MDO Meeting / 12th Europea...
juin 02-juin 05 - Vancouver, British Columbia - CALAS
juin 05-juin 05 - King of Prussia, Pennsylvania - Assessment of Immunomodulation for Bi...
juin 05-juin 08 - Saint Germain sur l’Arbresle, France - Charles River LAL Seminar Seri...
view all
RMS Specialist Montreal, Canada

Charles River Laboratories, Inc.